Payment overview · 2025
General Payments
$505.81
27 reported records · 10 companies
Healthcare provider profile · identity verified
John Bertini, DO
Allopathic & Osteopathic Physicians|Internal Medicine · ENDWELL, NY · NPI 1225267982
Verified facts
What the public records show
CMS Open Payments records show John Bertini, DO received $505.81 in general payments during 2025 across 27 reported records.
ABBVIE INC. accounted for 22.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Linzess, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 275 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $113.71 | 22.5% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $109.99 | 21.8% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $93.58 | 18.5% | 6 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $47.22 | 9.3% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $39.56 | 7.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.80 | 7.5% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.41 | 3.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.20 | 3.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.95 | 3.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.39 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $505.81 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $71.39 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $70.80 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $59.20 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $59.20 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $47.22 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $39.56 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.60 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $38.60 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $34.51 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.78 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 99 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 108 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
99 | 99 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
55 | 48 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
66 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
108 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
275 | 87 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
34 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1166 | 344 |
| Amlodipine Besylate | Amlodipine Besylate | 564 | 182 |
| Levothyroxine Sodium | Levothyroxine Sodium | 484 | 137 |
| Metoprolol Succinate | Metoprolol Succinate | 449 | 141 |
| Omeprazole | Omeprazole | 412 | 131 |
| Lisinopril | Lisinopril | 392 | 115 |
| Pantoprazole Sodium | Pantoprazole Sodium | 356 | 113 |
| Hydrochlorothiazide | Hydrochlorothiazide | 298 | 92 |
| Tamsulosin Hcl | Tamsulosin Hcl | 292 | 97 |
| Valsartan | Valsartan | 288 | 90 |
| Eliquis | Apixaban | 275 | 87 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 236 | 69 |
| Losartan Potassium | Losartan Potassium | 223 | 68 |
| Carvedilol | Carvedilol | 194 | 67 |
| Pravastatin Sodium | Pravastatin Sodium | 191 | 65 |
| Metformin Hcl | Metformin Hcl | 187 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 186 | 73 |
| Simvastatin | Simvastatin | 186 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 183 | 73 |
| Furosemide | Furosemide | 181 | 60 |
| Montelukast Sodium | Montelukast Sodium | 171 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 170 | 60 |
| Gabapentin | Gabapentin | 167 | 64 |
| Metformin Hcl Er | Metformin Hcl | 158 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 157 | 48 |
| Famotidine | Famotidine | 145 | 64 |
| Lorazepam | Lorazepam | 138 | 37 |
| Atenolol | Atenolol | 126 | 41 |
| Oxycodone Hcl | Oxycodone Hcl | 122 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 115 | 29 |
| Allopurinol | Allopurinol | 110 | 30 |
| Ozempic | Semaglutide | 108 | 30 |
| Trazodone Hcl | Trazodone Hcl | 105 | 46 |
| Sertraline Hcl | Sertraline Hcl | 101 | 34 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 99 | 99 |
| Jardiance | Empagliflozin | 97 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 97 | 29 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 96 | 32 |
| Spironolactone | Spironolactone | 96 | 31 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 95 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 95 | 24 |
| Mirtazapine | Mirtazapine | 93 | 29 |
| Xarelto | Rivaroxaban | 92 | 29 |
| Irbesartan | Irbesartan | 90 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 33 |
| Prednisone | Prednisone | 88 | 65 |
| Finasteride | Finasteride | 86 | 21 |
| Glimepiride | Glimepiride | 86 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 28 |
| Ezetimibe | Ezetimibe | 74 | 28 |
| Warfarin Sodium | Warfarin Sodium | 73 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 72 | 18 |
| Meloxicam | Meloxicam | 69 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 68 | 25 |
| Meclizine Hcl | Meclizine Hcl | 68 | 31 |
| Tramadol Hcl | Tramadol Hcl | 66 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | 16 |
| Alprazolam | Alprazolam | 61 | 29 |
| Clonazepam | Clonazepam | 59 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 56 | 18 |
| Mounjaro | Tirzepatide | 55 | suppressed |
| Ramipril | Ramipril | 55 | 17 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 55 | 48 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 16 |
| Torsemide | Torsemide | 54 | 19 |
| Baclofen | Baclofen | 53 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 14 |
| Bupropion Xl | Bupropion Hcl | 46 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 15 |
| Synthroid | Levothyroxine Sodium | 43 | 12 |
| Celecoxib | Celecoxib | 41 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 41 | 22 |
| Glipizide Er | Glipizide | 41 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | suppressed |
| Digoxin | Digoxin | 35 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 34 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Lansoprazole | Lansoprazole | 33 | suppressed |
| Potassium Chloride | Potassium Chloride | 32 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | 13 |
| Linzess | Linaclotide | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | 11 |
| Januvia | Sitagliptin Phosphate | 30 | 11 |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | 12 |
| Aripiprazole | Aripiprazole | 28 | 11 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 26 | suppressed |
| Epinephrine | Epinephrine | 26 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 12 |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | 13 |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 20 |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 22 |
| Naloxone Hcl | Naloxone Hcl | 23 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | 11 |
| Carbamazepine Er | Carbamazepine | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 19 | 19 |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | 12 |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 11 |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Xolair | Omalizumab | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Levocarnitine | Levocarnitine | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $505.81 · 27 records | ABBVIE INC. | ABRYSVO, AREXVY, COMIRNATY, CREON, Cologuard Collection Kit, FREESTYLE LIBRE 3, GEMTESA, INSPIRE, LINZESS, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error